XIAMEN LP PHARM CO
GenericsXIAMEN LP PHARM CO is a generic drug manufacturer focused on Neurology. Key products include OPIPZA.
XIAMEN LP PHARM CO's Key Drugs
XIAMEN LP PHARM CO's core commercial portfolio centers on OPIPZA, MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, spanning Neurology — its most strategically important drugs approved in the last 15 years.
XIAMEN LP PHARM CO's Recent FDA Approvals
XIAMEN LP PHARM CO secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
XIAMEN LP PHARM CO's Therapeutic Areas
XIAMEN LP PHARM CO's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
XIAMEN LP PHARM CO's Top Competitors
XIAMEN LP PHARM CO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
XIAMEN LP PHARM CO Pipeline Snapshot
Active clinical trials for XIAMEN LP PHARM CO across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OPIPZA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2017-11-20
- Latest
- 2025-08-06
- Applications
- 6